A team of British physicians has found a therapy that may eventually take the place of surgery, significantly improve the prognosis for bowel cancer patients, and dissolve tumors.
Physicians used the medication “Pembrolizumab,” which targets a particular protein and prevents it from being absorbed by immune cells, seeking out and eliminating cancer cells in clinical trials.
According to The Guardian, a clinical trial indicated that administering the medication before surgery rather than chemotherapy resulted in a notable rise in the number of patients who were deemed cancer-free.
The University of Glasgow, St. James’s Hospital, Southampton University Hospital, Christie NHS Foundation Trust, University College London, and University College London Hospital oversaw the study.
The Christie Foundation’s consultant clinical oncologist, Professor Mark Saunders, stated that the trial’s outcomes were encouraging and that preoperative immunotherapy “may become a radical change in the treatment of patients with this type of cancer.” Not only is the result superior, but it also spares patients from the more side-effect-prone conventional chemotherapy.
The researchers observed that roughly 15% of the individuals under study had a unique genetic composition while studying 32 patients with second- or third-stage bowel cancer across five hospitals in the United Kingdom.
The patients were observed over time after receiving pembrolizumab, commonly referred to as Keytruda, for nine weeks before surgery as an alternative to chemotherapy and surgery.
